Who is sponsoring NCT06567821?

NCT06567821 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT06567821?

Interventions in NCT06567821: RELIEVA SPINPLUS® NAV Balloon Sinusplasty System.

What condition does NCT06567821 study?

NCT06567821 studies Chronic Maxillary Rhinosinusitis.

Is NCT06567821 still recruiting?

NCT06567821 is currently recruiting now. Last updated 11 March 2026.

Last reviewed 2026-03-11 · How we verify

NCT06567821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using Navigation to Improve Accuracy of Maxillary Balloon Sinusotomy

Recruiting now Phase 2, PHASE3 Last updated 11 March 2026

What this trial tests

Phase 2, PHASE3 trial testing RELIEVA SPINPLUS® NAV Balloon Sinusplasty System in Chronic Maxillary Rhinosinusitis in 50 participants. Currently enrolling.

Timeline

4 September 2024

Primary endpoint
1 October 2027

31 December 2027

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Phase	Phase 2, PHASE3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	other
Enrollment	50
Start date	4 September 2024
Primary completion	1 October 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

RELIEVA SPINPLUS® NAV Balloon Sinusplasty System

Conditions studied

Chronic Maxillary Rhinosinusitis — all drugs for Chronic Maxillary Rhinosinusitis →

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Chronic Maxillary Rhinosinusitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the research is to examine the effectiveness of navigation in maxillary sinus balloon dilation for the treatment of chronic maxillary rhinosinusitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06567821 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 11 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06567821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing